PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
7.01%
Net income growth under 50% of TRVN's 53.49%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
8.54%
Some D&A expansion while TRVN is negative at -62.23%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Well above TRVN's 100.00% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
48.65%
SBC growth while TRVN is negative at -7.09%. John Neff would see competitor possibly controlling share issuance more tightly.
-142.09%
Both reduce yoy usage, with TRVN at -126.93%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-124.49%
Both negative yoy AP, with TRVN at -129.79%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-84.29%
Both reduce yoy usage, with TRVN at -124.93%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
47.93%
Some yoy increase while TRVN is negative at -107.21%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
1.55%
Some CFO growth while TRVN is negative at -57.39%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut debt repayment yoy while TRVN is 99.98%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1131.77%
We slightly raise equity while TRVN is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.